<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>SYLATRON- peginterferon alfa-2b 
			 </strong><br>Merck Sharp &amp; Dohme Corp.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use SYLATRON safely and effectively. See full prescribing information for SYLATRON. <br><br>SYLATRON™ (peginterferon alfa-2b) <br>for injection, for subcutaneous use <br>Initial U.S. Approval: 2011</div>
<div class="Warning"><div>
<h1 class="Warning">WARNING: <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">DEPRESSION</span> AND OTHER NEUROPSYCHIATRIC DISORDERS</h1>
<h1 class="Warning"><span class="Italics">See full prescribing information for complete boxed warning.</span></h1>
<p class="Highlighta"><span class="Bold">The risk of serious <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, with <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span> and <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">completed suicides</span>, and other serious neuropsychiatric disorders are increased with alpha interferons, including SYLATRON. Permanently discontinue SYLATRON in patients with persistently severe or worsening signs or symptoms of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>, or <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span>. These disorders may not resolve after stopping SYLATRON <span class="Italics">[see <a href="#S5.1">Warnings and Precautions (5.1)</a> and <a href="#S6.1">Adverse Reactions (6.1)</a>].</span></span> </p>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><table class="Noautorules" width="100%">
<col align="left" valign="bottom" width="70%">
<col align="right" valign="bottom" width="30%">
<tbody class="Headless">
<tr>
<td align="left">Dosage and Administration</td>
<td align="right"></td>
</tr>
<tr>
<td align="left">  Recommended Dosing  (<a href="#S2.1">2.1</a>) </td>
<td align="right">8/2014</td>
</tr>
<tr>
<td align="left">  Preparation and Administration (<a href="#S2.3">2.3</a>) </td>
<td align="right">8/2014</td>
</tr>
<tr>
<td align="left">Warnings and Precautions</td>
<td align="right"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> and Other Serious Neuropsychiatric Adverse Reactions  (<a href="#S5.1">5.1</a>) </td>
<td align="right">5/2015</td>
</tr>
</tbody>
</table></div>
</div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning">WARNING: <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">DEPRESSION</span> AND OTHER NEUROPSYCHIATRIC DISORDERS</h1>
<h1 class="Warning"><span class="Italics">See full prescribing information for complete boxed warning.</span></h1>
<p class="Highlighta"><span class="Bold">The risk of serious <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, with <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span> and <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">completed suicides</span>, and other serious neuropsychiatric disorders are increased with alpha interferons, including SYLATRON. Permanently discontinue SYLATRON in patients with persistently severe or worsening signs or symptoms of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>, or <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span>. These disorders may not resolve after stopping SYLATRON <span class="Italics">[see <a href="#S5.1">Warnings and Precautions (5.1)</a> and <a href="#S6.1">Adverse Reactions (6.1)</a>].</span></span> </p>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">SYLATRON is an alpha interferon indicated for the adjuvant treatment of melanoma with microscopic or gross nodal involvement within 84 days of definitive surgical resection including complete lymphadenectomy. (<a href="#S1">1</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul>
<li>6 mcg/kg/week subcutaneously for 8 doses followed by;</li>
<li>3 mcg/kg/week subcutaneously for up to 5 years. (<a href="#S2.1">2.1</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul>
<li>200 mcg of deliverable lyophilized powder per single-use vial (<a href="#S3">3</a>)</li>
<li>300 mcg of deliverable lyophilized powder per single-use vial (<a href="#S3">3</a>)</li>
<li>600 mcg of deliverable lyophilized powder per single-use vial (<a href="#S3">3</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul>
<li>Known serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> to peginterferon alfa-2b or interferon alfa-2b. (<a href="#S4">4</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="200762" conceptname="Autoimmune hepatitis">Autoimmune hepatitis</span>. (<a href="#S4">4</a>)</li>
<li>Hepatic decompensation (Child-Pugh score &gt;6 [class B and C]). (<a href="#S4">4</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> and other serious neuropsychiatric adverse reactions. (<a href="#S5.1">5.1</a>)</li>
<li>History of significant or unstable cardiac disease. (<a href="#S5.2">5.2</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="378416" conceptname="Retinal disorder">Retinal disorders</span>. (<a href="#S5.3">5.3</a>)</li>
<li>Child-Pugh score &gt;6 (class B and C). (<a href="#S4">4</a>, <a href="#S5.4">5.4</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">Hypothyroidism</span>, <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span>, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus that cannot be effectively treated by medication. (<a href="#S4">4</a>, <a href="#S5.5">5.5</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions (&gt;60%) are: <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, increased ALT, increased AST, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, and <span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">injection site reaction</span>. (<a href="#S6.1">6.1</a>) </p>
<br><p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Schering Corporation at 1-800-526-4099 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul><li>Drugs metabolized by cytochrome P-450 (CYP) enzymes: Monitor for potential increased toxicities of drugs with a narrow therapeutic range metabolized by CYP1A2 or CYP2D6 when coadministered with SYLATRON. (<a href="#S7">7</a>)</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul>
<li>Pregnancy: Based on animal data, may cause fetal harm. (<a href="#S8.1">8.1</a>)</li>
<li>Pediatrics: Safety and efficacy in patients &lt;18 years old have not been established. (<a href="#S8.4">8.4</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>: Reduce the dose of SYLATRON by 25% in patients with moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> and 50% in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> or end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> (ESRD) requiring dialysis. (<a href="#S2.1">2.1</a>, <a href="#S8.7">8.7</a>)</li>
</ul></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div>
<div></div>
<div></div>
</div>
</div>
<div><div>
<div></div>
<div></div>
</div></div>
<div></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 5/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc"><span class="Emphasis">WARNING: <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">DEPRESSION</span> AND OTHER NEUROPSYCHIATRIC DISORDERS</span></a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1	Recommended Dosing</a></h2>
<h2><a href="#section-2.2" class="toc">2.2	Dose Modification Guidelines</a></h2>
<h2><a href="#section-2.3" class="toc">2.3	Preparation and Administration</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1	<span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> and Other Serious Neuropsychiatric Adverse Reactions</a></h2>
<h2><a href="#section-5.2" class="toc">5.2	Cardiovascular Adverse Reactions</a></h2>
<h2><a href="#section-5.3" class="toc">5.3	<span class="product-label-link" type="condition" conceptid="376103" conceptname="Retinopathy">Retinopathy</span> and Other Serious Ocular Adverse Reactions</a></h2>
<h2><a href="#section-5.4" class="toc">5.4	<span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Failure</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5	Endocrinopathies</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1	Clinical Trials Experience </a></h2>
<h2><a href="#section-6.2" class="toc">6.2	Immunogenicity</a></h2>
<h2><a href="#section-6.3" class="toc">6.3	Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6	<span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-8.6" class="toc">8.7	<span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="BOX"></a><a name="section-1"></a><p></p>
<h1><span class="Emphasis">WARNING: <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">DEPRESSION</span> AND OTHER NEUROPSYCHIATRIC DISORDERS</span></h1>
<p class="First"><span class="Bold">The risk of serious <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, with <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span> and <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">completed suicides</span>, and other serious neuropsychiatric disorders are increased with alpha interferons, including SYLATRON. Permanently discontinue SYLATRON in patients with persistently severe or worsening signs or symptoms of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>, or <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span>. These disorders may not resolve after stopping SYLATRON <span class="Italics">[see <a href="#S5.1">Warnings and Precautions (5.1)</a> and <a href="#S6.1">Adverse Reactions (6.1)</a>].</span></span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">SYLATRON<span class="Bold">™</span> is an alpha interferon indicated for the adjuvant treatment of melanoma with microscopic or gross nodal involvement within 84 days of definitive surgical resection including complete lymphadenectomy.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1	Recommended Dosing</h2>
<ul>
<li>The recommended starting dose is 6 mcg/kg/week subcutaneously for 8 doses, followed by 3 mcg/kg/week subcutaneously for up to 5 years.</li>
<li>Premedicate with acetaminophen 500 to 1000 mg orally 30 minutes prior to the first dose of SYLATRON and as needed for subsequent doses.</li>
<li style="border-left:1px solid;"><span class="XmChange">The recommended starting doses of SYLATRON in patients with moderate or severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> or end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> (ESRD) are listed in Table 1 <span class="Italics">[see <a href="#S8.7">Use in Specific Populations (8.7)</a>].</span> No dose adjustment is needed for patients with a creatinine clearance (CLcr) &gt; 50 mL/min/1.73m<span class="Sup">2</span>.</span></li>
</ul>
<a name="table1"></a><table width="85%">
<caption><span>Table 1: Recommended Starting Dose for Moderate and Severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> and End-Stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">Renal Disease</span></span></caption>
<col align="left" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center"><span class="XmChange">Degree of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></th>
<th class="Rrule" align="center">Creatinine Clearance (mL/min/1.73m<span class="Sup">2</span>)</th>
<th class="Rrule" align="center">Initial doses for 8 weeks</th>
<th class="Rrule" align="center">Follow-up doses for 5 years</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="XmChange">Moderate</span></td>
<td class="Rrule" align="center">30 – 50</td>
<td class="Rrule" align="center">4.5 mcg/kg/week</td>
<td class="Rrule" align="center">2.25 mcg/kg/week</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="XmChange">Severe</span></td>
<td class="Rrule" align="center">&lt;30</td>
<td class="Rrule" align="center">3 mcg/kg/week</td>
<td class="Rrule" align="center">1.5 mcg/kg/week</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class="XmChange">End-Stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">Renal Disease</span></span></td>
<td class="Rrule" align="center">On dialysis</td>
<td class="Rrule" align="center">3 mcg/kg/week</td>
<td class="Rrule" align="center">1.5 mcg/kg/week</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2	Dose Modification Guidelines</h2>
<p class="First">Guidelines for Dose Modification provided below are based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE Version 2.0).</p>
<ul>
<li>Permanently discontinue SYLATRON for: 							<ul class="Circle">
<li>Persistent or worsening severe neuropsychiatric disorders</li>
<li>Grade 4 non-hematologic toxicity</li>
<li>Inability to tolerate a dose of 1 mcg/kg/wk</li>
<li>New or worsening <span class="product-label-link" type="condition" conceptid="376103" conceptname="Retinopathy">retinopathy</span></li>
</ul>
</li>
<li>Withhold SYLATRON dose for any of the following: 							<ul class="Circle">
<li>Absolute Neutrophil Count (ANC) less than 0.5×10<span class="Sup">9</span>/L</li>
<li>Platelet Count (PLT) less than 50×10<span class="Sup">9</span>/L</li>
<li>ECOG PS greater than or equal to 2</li>
<li>Non-hematologic toxicity greater than or equal to Grade 3</li>
</ul>
</li>
<li>Resume dosing at a reduced dose (see <a href="#table1">Table 1</a>) when all of the following are present: 							<ul class="Circle">
<li>Absolute Neutrophil Count (ANC) greater than or equal to 0.5×10<span class="Sup">9</span>/L</li>
<li>Platelet Count (PLT) greater than or equal to 50×10<span class="Sup">9</span>/L</li>
<li>ECOG PS 0-1</li>
<li>Non-hematologic toxicity has completely resolved or improved to Grade 1</li>
</ul>
</li>
</ul>
<a name="table2"></a><table width="75%">
<caption><span>Table 2: SYLATRON Dose Modifications</span></caption>
<col align="center" valign="top" width="25%">
<col align="left" valign="top" width="75%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center">Starting Dose</th>
<th class="Rrule" align="left">Dose Modifications for Doses 1 to 8</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Lrule Rrule" align="center">6 mcg/kg/week</td>
<td class="Rrule" align="left">  First Dose Modification: 3 mcg/kg/week</td>
</tr>
<tr>
<td class="Lrule Rrule" align="center"></td>
<td class="Rrule Toprule" align="left">  Second Dose Modification: 2 mcg/kg/week</td>
</tr>
<tr>
<td class="Lrule Rrule" align="center"></td>
<td class="Rrule Toprule" align="left">  Third Dose Modification: 1 mcg/kg/week</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"></td>
<td class="Rrule Toprule" align="left">  Permanently discontinue if unable to tolerate 1 mcg/kg/week</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="Bold">Starting Dose</span></td>
<td class="Rrule" align="left"><span class="Bold">Dose Modifications for Doses 9 to 260 </span></td>
</tr>
<tr>
<td class="Lrule Rrule" align="center">3 mcg/kg/week</td>
<td class="Rrule" align="left">  First Dose Modification: 2 mcg/kg/week</td>
</tr>
<tr>
<td class="Lrule Rrule" align="center"></td>
<td class="Rrule Toprule" align="left">  Second Dose Modification: 1 mcg/kg/week</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center"></td>
<td class="Rrule Toprule" align="left">  Permanently discontinue if unable to tolerate 1 mcg/kg/week</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.3"></a><a name="section-2.3"></a><p></p>
<h2>2.3	Preparation and Administration</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Reconstitute SYLATRON with 0.7 mL of Sterile Water for Injection, USP. The Sterile Water for Injection supplied contains 5 mL. Each vial of Sterile Water for Injection is intended for single use. Discard any unused Sterile Water for Injection, USP.</span></p>
<a name="table3"></a><table width="85%">
<caption><span>Table 3: Reconstitution of SYLATRON Single-Use Vials</span></caption>
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="10%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="5%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center">SYLATRON Single-Use Vial</th>
<th class="Rrule" align="center"></th>
<th class="Rrule" align="center">Diluent (Sterile Water for Injection, USP)</th>
<th class="Rrule" align="center"></th>
<th class="Rrule" align="center">Deliverable Product and Volume</th>
<th class="Rrule" align="center">Final Concentration</th>
</tr></thead>
<tfoot><tr><td colspan="6" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Total vial content of SYLATRON is 296 mcg.</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>Total vial content of SYLATRON is 444 mcg.</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">‡</a></dt>
<dd>Total vial content of SYLATRON is 888 mcg.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="center">200 mcg<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>
</td>
<td class="Rrule" align="center">add</td>
<td class="Rrule" align="center">0.7 mL</td>
<td class="Rrule" align="center">=</td>
<td class="Rrule" align="center">200 mcg in 0.5 mL </td>
<td class="Rrule" align="center">40 mcg/0.1 mL</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">300 mcg<a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a>
</td>
<td class="Rrule" align="center">add</td>
<td class="Rrule" align="center">0.7 mL</td>
<td class="Rrule" align="center">=</td>
<td class="Rrule" align="center">300 mcg in 0.5 mL </td>
<td class="Rrule" align="center">60 mcg/0.1 mL</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center">600 mcg<a name="footnote-reference-3" href="#footnote-3" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">add</td>
<td class="Rrule" align="center">0.7 mL</td>
<td class="Rrule" align="center">=</td>
<td class="Rrule" align="center">600 mcg in 0.5 mL </td>
<td class="Rrule" align="center">120 mcg/0.1 mL</td>
</tr>
</tbody>
</table>
<ul>
<li>Swirl gently to dissolve the lyophilized powder. <span class="Bold">DO NOT SHAKE.</span>
</li>
<li>Visually inspect the solution for particulate matter and discoloration prior to administration. Discard if solution is discolored, cloudy, or if particulates are present.</li>
<li>Do not withdraw more than 0.5 mL of reconstituted solution from each vial.</li>
<li>Administer SYLATRON subcutaneously. Rotate injection sites.</li>
<li>If reconstituted solution is not used immediately, store at 2°-8°C (36°-46°F) for no more than 24 hours. Discard reconstituted solution after 24 hours. <span class="Bold">DO NOT FREEZE.</span>
</li>
<li>For single-use only. <span class="Bold">DISCARD ANY UNUSED PORTION.</span>
</li>
</ul>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<ul>
<li>200 mcg of deliverable lyophilized powder per single-use vial</li>
<li>300 mcg of deliverable lyophilized powder per single-use vial</li>
<li>600 mcg of deliverable lyophilized powder per single-use vial</li>
</ul>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">SYLATRON is contraindicated in patients with:</p>
<ul>
<li>A history of <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> to peginterferon alfa-2b or interferon alfa-2b</li>
<li><span class="product-label-link" type="condition" conceptid="200762" conceptname="Autoimmune hepatitis">autoimmune hepatitis</span></li>
<li>hepatic decompensation (Child-Pugh score &gt;6 [class B and C])</li>
</ul>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1	<span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> and Other Serious Neuropsychiatric Adverse Reactions</h2>
<p class="First">Peginterferon alfa-2b can cause life-threatening or fatal neuropsychiatric reactions. These include <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>, suicidal and <span class="product-label-link" type="condition" conceptid="4024763" conceptname="Homicidal thoughts">homicidal ideation</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, and an increased risk of relapse of recovering drug addicts. In the clinical trial, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> occurred in 59% of SYLATRON-treated patients and 24% of patients in the observation group. <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> was severe or life threatening in 7% of SYLATRON-treated patients compared with &lt;1% of patients in the observation arm.</p>
<p>In post-marketing experience, neuropsychiatric adverse reactions have been reported up to 6 months after discontinuation of peginterferon alfa-2b. Based on post-marketing experience with peginterferon alfa-2b and interferon alfa-2b, treatment may also result in <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressive behavior</span>, psychoses, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, bipolar disorders, <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>, and <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span>.</p>
<p style="border-left:1px solid;"><span class="XmChange">Advise patients and their caregivers to immediately report any symptoms of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span> to their healthcare provider. Monitor and evaluate patients for signs and symptoms of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and other <span class="product-label-link" type="condition" conceptid="4294810" conceptname="Psychiatric symptom">psychiatric symptoms</span> every 3 weeks during the first 8 weeks of treatment and every 6 months thereafter. Monitor patients during treatment and for at least 6 months after the last dose of SYLATRON. Permanently discontinue SYLATRON for suicidal or <span class="product-label-link" type="condition" conceptid="4024763" conceptname="Homicidal thoughts">homicidal ideation</span>, <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressive behavior</span> towards others, or other severe or persistent <span class="product-label-link" type="condition" conceptid="4294810" conceptname="Psychiatric symptom">psychiatric symptoms</span>; institute psychiatric intervention and follow-up as appropriate.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2	Cardiovascular Adverse Reactions</h2>
<p class="First">In the clinical trial, cardiac adverse reactions, including <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, bundle-branch block, <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span>, and supraventricular <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span> occurred in 4% of SYLATRON-treated patients compared with 2% of patients in the observation group. In post-marketing experience, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span>, and <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span> have occurred in patients treated with peginterferon alfa-2b.</p>
<p>Permanently discontinue SYLATRON for new onset of <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmia</span> or cardiovascular decompensation.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3	<span class="product-label-link" type="condition" conceptid="376103" conceptname="Retinopathy">Retinopathy</span> and Other Serious Ocular Adverse Reactions</h2>
<p class="First">Peginterferon alfa-2b can cause decrease in visual acuity or <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">blindness</span> due to <span class="product-label-link" type="condition" conceptid="376103" conceptname="Retinopathy">retinopathy</span>. Retinal and ocular changes include <span class="product-label-link" type="condition" conceptid="4290333" conceptname="Macular retinal edema">macular edema</span>, retinal artery or vein <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>, <span class="product-label-link" type="condition" conceptid="374025" conceptname="Retinal hemorrhage">retinal hemorrhages</span> and <span class="product-label-link" type="condition" conceptid="4220027" conceptname="Cotton wool spots">cotton wool spots</span>, <span class="product-label-link" type="condition" conceptid="374954" conceptname="Optic neuritis">optic neuritis</span>, <span class="product-label-link" type="condition" conceptid="4308632" conceptname="Optic disc edema">papilledema</span>, and <span class="product-label-link" type="condition" conceptid="374640" conceptname="Serous retinal detachment">serous retinal detachment</span> may be induced or aggravated by treatment with peginterferon alfa-2b or other alpha interferons. In the clinical study, two SYLATRON-treated patients developed partial <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span> due to retinal <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> (n=1) or <span class="product-label-link" type="condition" conceptid="376103" conceptname="Retinopathy">retinopathy</span> (n=1). The overall incidence of serious <span class="product-label-link" type="condition" conceptid="378416" conceptname="Retinal disorder">retinal disorders</span>, <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, and reduction in visual acuity was &lt;1% in both SYLATRON-treated patients and the observation group.</p>
<p>Perform an eye examination that includes assessment of visual acuity and indirect ophthalmoscopy or fundus photography at baseline in patients with preexisting <span class="product-label-link" type="condition" conceptid="376103" conceptname="Retinopathy">retinopathy</span> and at any time during SYLATRON treatment in patients who experience changes in vision. Permanently discontinue SYLATRON in patients who develop new or worsening <span class="product-label-link" type="condition" conceptid="376103" conceptname="Retinopathy">retinopathy</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4	<span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Failure</span></h2>
<p class="First">Peginterferon alfa-2b, increases the risk of hepatic decompensation and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in patients with cirrhosis. Monitor hepatic function with serum bilirubin, ALT, AST, alkaline phosphatase, and LDH at 2 and 8 weeks, and 2 and 3 months following initiation of SYLATRON, then every 6 months while receiving SYLATRON. Permanently discontinue SYLATRON for evidence of severe (Grade 3) hepatic injury or hepatic decompensation (Child-Pugh score &gt;6 [class B and C]) <span class="Italics">[see <a href="#S4">Contraindications (4)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5	Endocrinopathies</h2>
<p class="First">Peginterferon alfa-2b can cause new onset or worsening of <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>, <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span>, and <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus. In the clinical study, 1% of patients developed <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>; the overall incidence of <span class="product-label-link" type="condition" conceptid="31821" conceptname="Disorder of endocrine system">endocrine disorders</span> was 2% in SYLATRON-treated patients compared to &lt;1% for patients in the observation group.</p>
<p>Obtain TSH levels within 4 weeks prior to initiation of SYLATRON, at 3 and 6 months following initiation, then every 6 months thereafter while receiving SYLATRON. Permanently discontinue SYLATRON in patients who develop <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>, <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span> or <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus that cannot be effectively managed.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following serious adverse reactions are discussed in greater detail in other sections of the labeling:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> and Other Neuropsychiatric Adverse Reactions <span class="Italics">[see <a href="#S5.1">Warnings and Precautions (5.1)</a>]</span>
</li>
<li>Cardiovascular Adverse Reactions <span class="Italics">[see <a href="#S5.2">Warnings and Precautions (5.2)</a>]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="376103" conceptname="Retinopathy">Retinopathy</span> and Other Serious Ocular Adverse Reactions <span class="Italics">[see <a href="#S5.3">Warnings and Precautions (5.3)</a>]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Failure</span> <span class="Italics">[see <a href="#S5.4">Warnings and Precautions (5.4)</a>]</span>
</li>
<li>Endocrinopathies <span class="Italics">[see <a href="#S5.5">Warnings and Precautions (5.5)</a>]</span>
</li>
</ul>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1	Clinical Trials Experience </h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</p>
<p>The data described below reflect exposure to SYLATRON in 608 patients with surgically resected, AJCC Stage III melanoma. SYLATRON was studied in an open label, multicenter, randomized, observation controlled trial. The median age of the population was 50 years with 10% of patients 65 years or older, and 42% were female. Fourteen percent of patients completed the 5 year treatment schedule.</p>
<p>Patients randomized to SYLATRON were to receive total doses of 48 mcg/kg (6 mcg/kg subcutaneous once weekly for 8 doses), and 780 mcg/kg (3 mcg/kg subcutaneous once weekly until disease recurrence or for up to 5 years), as tolerated. The median total dose received was 42 mcg/kg (range: 6 to 78 mcg/kg) for the first 8 doses, and 136 mcg/kg (range: 1 to 774 mcg/kg) for doses 9 to 260.</p>
<p>Serious adverse events were reported in 199 (33%) patients who received SYLATRON and 94 (15%) patients in the observation group.</p>
<p>The most common adverse reactions experienced by SYLATRON-treated patients were <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> (94%), increased ALT (77%), increased AST (77%), <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span> (75%), <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (70%), <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span> (69%), <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span> (68%), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (64%), <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span> (63%), and <span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">injection site reaction</span> (62%). The most common serious adverse reactions were <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> (7%), increased ALT (3%), increased AST (3%), and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span> (3%) in the SYLATRON-treated group vs. &lt;1% in the observation group for these reactions.</p>
<p>Thirty three percent of patients receiving SYLATRON discontinued treatment due to adverse reactions. The most common adverse reactions present at the time of treatment discontinuation were <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> (27%), <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> (17%), <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span> (15%), increased ALT (14%), increased AST (14%), <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span> (13%), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (13%), <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (13%), and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span> (11%). Adverse events that occurred in the clinical study at ≥ 5% incidence in the SYLATRON-treated group and with a greater incidence in patients receiving SYLATRON as compared to the observation group are presented in <span class="Bold">Table 4</span>.</p>
<a name="table4"></a><table width="75%">
<caption><span>Table 4: Incidence of Adverse Reactions<span class="Sup">(</span><a name="footnote-reference-4" href="#footnote-4" class="Sup">*</a><span class="Sup">)</span> Occurring in ≥ 5% of Melanoma Patients Treated with SYLATRON and with a Greater Incidence as Compared to Observation</span></caption>
<col align="center" valign="middle" width="48%">
<col align="center" valign="middle" width="13%">
<col align="center" valign="middle" width="13%">
<col align="center" valign="middle" width="13%">
<col align="center" valign="middle" width="13%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="center" valign="middle">Adverse  Reaction</th>
<th class="Rrule" align="center" colspan="2">SYLATRON<br>N=608</th>
<th class="Rrule" align="center" colspan="2">Observation<br>N=628</th>
</tr>
<tr class="Botrule Last">
<th class="Lrule Rrule" align="center"></th>
<th class="Rrule" align="center">All <br>Grades<br>(%)</th>
<th class="Rrule" align="center">Grade <br>3 and 4<br>(%)</th>
<th class="Rrule" align="center">All <br>Grades<br>(%)</th>
<th class="Rrule" align="center">Grade <br>3 and 4<br>(%)</th>
</tr>
</thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-4" href="#footnote-reference-4">*</a></dt>
<dd><span class="Bold">Adverse reactions were graded using NCI CTCAE, V.2.0.</span></dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="center">Any Adverse Reaction</td>
<td class="Rrule" align="center">100</td>
<td class="Rrule" align="center">51</td>
<td class="Rrule" align="center">82</td>
<td class="Rrule" align="center">18</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="Bold">General Disorders and Administrative Site Conditions</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td class="Rrule" align="center">94</td>
<td class="Rrule" align="center">16</td>
<td class="Rrule" align="center">41</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span></td>
<td class="Rrule" align="center">75</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">Chills</span></td>
<td class="Rrule" align="center">63</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">Injection Site Reaction</span></td>
<td class="Rrule" align="center">62</td>
<td class="Rrule" align="center">1.8</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="Bold">Metabolic/Laboratory</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">ALT or AST Increased</td>
<td class="Rrule" align="center">77</td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">26</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">Blood Alkaline Phosphatase Increased</td>
<td class="Rrule" align="center">23</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">&lt;1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">Weight Decreased</span></td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">&lt;1</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">&lt;1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="product-label-link" type="condition" conceptid="4171925" conceptname="Gamma-glutamyl transferase raised">GGT Increased</span></td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">&lt;1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">Proteinuria</span></td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span></td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">&lt;1</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">&lt;1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Rrule" align="center">70</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">19</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">Dysgeusia</span></td>
<td class="Rrule" align="center">38</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Rrule" align="center">35</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">&lt;1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="product-label-link" type="condition" conceptid="435253" conceptname="Disorder of olfactory nerve">Olfactory Nerve Disorder</span></td>
<td class="Rrule" align="center">23</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paraesthesia</span></td>
<td class="Rrule" align="center">21</td>
<td class="Rrule" align="center">&lt;1</td>
<td class="Rrule" align="center">14</td>
<td class="Rrule" align="center">&lt;1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="Bold">Metabolism and Nutrition Disorders</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></td>
<td class="Rrule" align="center">69</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">13</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="Bold">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">Connective Tissue Disorders</span></span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></td>
<td class="Rrule" align="center">68</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">23</td>
<td class="Rrule" align="center">&lt;1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></td>
<td class="Rrule" align="center">51</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">22</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Rrule" align="center">64</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">&lt;1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Rrule" align="center">37</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">&lt;1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Rrule" align="center">26</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="Bold">Psychiatric Disorders</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></td>
<td class="Rrule" align="center">59</td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">24</td>
<td class="Rrule" align="center">&lt;1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="Bold">Skin and Subcutaneous Tissue Disorders</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">Exfoliative <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td class="Rrule" align="center">36</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span></td>
<td class="Rrule" align="center">34</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="Bold">Respiratory, Thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">Mediastinal Disorders</span></span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">&lt;1</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">0</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.2"></a><a name="section-6.2"></a><p></p>
<h2>6.2	Immunogenicity</h2>
<p class="First">As with all therapeutic proteins, there is potential for immunogenicity. In a clinical study conducted in patients with melanoma, the incidence of binding antibodies to peg-interferon alfa-2b was approximately 35% (50/144 patients). Among the patients who tested positive for binding antibodies, one patient developed neutralizing antibodies. The impact of antibody formation on pharmacokinetics, safety and efficacy of peg-interferon alfa-2b could not be assessed based on limited available data.</p>
<p>The incidence of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors, including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to SYLATRON with the incidence of antibodies to other products may be misleading.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.3"></a><a name="section-6.3"></a><p></p>
<h2>6.3	Postmarketing Experience</h2>
<p class="First">The following adverse reactions have been identified during post-approval use of peginterferon alfa-2b as monotherapy and in combination with ribavirin in <span class="product-label-link" type="condition" conceptid="198964" conceptname="Chronic hepatitis C">chronic hepatitis C</span> (CHC) patients. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<p><span class="Italics">Blood and Lymphatic System Disorders</span></p>
<p>pure <span class="product-label-link" type="condition" conceptid="4226622" conceptname="Decreased erythroid precursor production">red cell aplasia</span>, <span class="product-label-link" type="condition" conceptid="4301602" conceptname="Thrombotic thrombocytopenic purpura">thrombotic thrombocytopenic purpura</span></p>
<p><span class="Italics">Ear and Labyrinth Disorders</span></p>
<p><span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hearing loss</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, hearing impairment</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="31821" conceptname="Disorder of endocrine system">Endocrine Disorders</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">diabetic ketoacidosis</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye Disorders</span></span></p>
<p>Vogt-Koyanagi-Harada syndrome</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="138463" conceptname="Aphthous ulcer of mouth">aphthous stomatitis</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span></p>
<p><span class="Italics">Infusion reactions</span></p>
<p><span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchoconstriction</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune System Disorders</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="133444" conceptname="Thyroiditis">thyroiditis</span>, <span class="product-label-link" type="condition" conceptid="4301602" conceptname="Thrombotic thrombocytopenic purpura">thrombotic thrombocytopenic purpura</span>, <span class="product-label-link" type="condition" conceptid="4120621" conceptname="Immune thrombocytopenic purpura">idiopathic thrombocytopenic purpura</span>, <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span>, interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span>, and <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> </span></p>
<p><span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span></p>
<p><span class="Italics">Metabolism and Nutrition Disorders</span></p>
<p><span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span></p>
<p><span class="Italics">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">Connective Tissue Disorders</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, <span class="product-label-link" type="condition" conceptid="73001" conceptname="Myositis">myositis</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">memory loss</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paraesthesia</span>, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headache</span></p>
<p><span class="Italics">Respiratory, Thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">Mediastinal Disorders</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, pulmonary infiltrates, <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, <span class="product-label-link" type="condition" conceptid="4222731" conceptname="Obliterative bronchiolitis">bronchiolitis obliterans</span>, <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">interstitial pneumonitis</span>, <span class="product-label-link" type="condition" conceptid="438688" conceptname="Sarcoidosis">sarcoidosis</span>, <span class="product-label-link" type="condition" conceptid="4322024" conceptname="Pulmonary hypertension">pulmonary hypertension</span>, and <span class="product-label-link" type="condition" conceptid="4197819" conceptname="Fibrosis of lung">pulmonary fibrosis</span></p>
<p><span class="Italics">Skin and Subcutaneous Tissue Disorders</span></p>
<p><span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular Disorders</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="S7"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">Peginterferon alfa-2b inhibits CYP1A2 and CYP2D6 activity. When caffeine (CYP1A2 substrate) or desipramine (CYP2D6 substrate) was coadministered with peginterferon alfa-2b (3 mcg/kg once weekly for two weeks), the exposure to caffeine increased 36% and the exposure to desipramine increased 30% as compared to when caffeine or desipramine was administered alone. Monitor for potential increased toxicities of drugs with a narrow therapeutic range metabolized by CYP1A2 or CYP2D6 when coadministered with SYLATRON. <span class="Italics">[See <a href="#S12.3">Clinical Pharmacology (12.3)</a>.]</span></p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="S8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.1"></a><p></p>
<p class="First"><span class="Bold Italics">Pregnancy Category C:</span></p>
<p>There are no adequate and well-controlled studies of SYLATRON in pregnant women. Nonpegylated interferon alfa-2b was an abortifacient in <span class="Italics">Macaca mulatta</span> (rhesus monkeys) at 15 and 30 million international units (IU)/kg (estimated human equivalent of 5 and 10 million IU/kg, based on body surface area adjustment for a 60-kg adult). The estimated Intron A human equivalent dose of 5 to 10 million IU/kg daily is approximately equal to a human equivalent dose of 79 to 158 mcg/kg/week of SYLATRON. Use SYLATRON during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="S8.3"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether the components of SYLATRON are excreted in human milk. Studies in mice have shown that mouse interferons are excreted in breast milk. Because of the potential for adverse reactions from the drug in nursing infants, a decision must be made whether to discontinue nursing or discontinue the SYLATRON treatment, taking into account the importance of the therapy to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="S8.4"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and effectiveness in patients below the age of 18 years have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="S8.5"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Clinical studies of SYLATRON did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.6"></a><a name="section-8.5"></a><p></p>
<h2>8.6	<span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">SYLATRON has not been studied in patients with melanoma who have <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. In patients treated for <span class="product-label-link" type="condition" conceptid="4291005" conceptname="Viral hepatitis">viral hepatitis</span>, peginterferon alfa-2b treatment is contraindicated in those with moderate or severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh scores &gt;6). Discontinue SYLATRON if hepatic decompensation (Child-Pugh scores &gt;6) occurs during treatment. <span class="Italics">[See <a href="#S4">Contraindications (4)</a> and <a href="#S5.4">Warnings and Precautions (5.4)</a>.]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.7"></a><a name="section-8.6"></a><p></p>
<h2>8.7	<span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Reduce the dose of SYLATRON by 25% in patients with moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CLcr 30 to 50 mL/min/1.73m<span class="Sup">2</span>) and 50% in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CLcr &lt; 30 mL/min/1.73m<span class="Sup">2</span>) or ESRD requiring dialysis <span class="Italics">[see <a href="#S2.1">Dosage and Administration (2.1)</a>]</span>. A study in subjects with varying degrees of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> showed that the mean exposure (AUC) to peginterferon alfa-2b increased in subjects with moderate and severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> or ESRD requiring dialysis, as compared to subjects with normal renal function (CLcr &gt; 80 mL/min/1.73m<span class="Sup">2</span>) following a single 4.5 mcg/kg dose of peginterferon alfa-2b <span class="Italics">[see <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="S10"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">The experience with <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of SYLATRON is limited. Patients who were over dosed experienced the following adverse reactions: severe <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>. The highest single dose administered was 14 mcg/kg.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="S11"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">SYLATRON, peginterferon alfa-2b, is a covalent conjugate of recombinant alfa-2b interferon with monomethoxy polyethylene glycol (PEG). The average molecular weight of the PEG portion of the molecule is 12,000 daltons. The average molecular weight of the SYLATRON molecule is approximately 31,000 daltons. The specific activity of pegylated interferon alfa-2b is approximately 0.7 × 10<span class="Sup">8</span> international units/mg protein.</p>
<p>Interferon alfa-2b is a protein with a molecular weight of 19,271 daltons produced by recombinant DNA techniques. It is obtained from the bacterial fermentation of a <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> of <span class="Italics">Escherichia coli</span> bearing a genetically engineered plasmid containing an interferon gene from human leukocytes.</p>
<p>Each vial contains either 296 mcg, 444 mcg or 888 mcg of peginterferon alfa-2b as a sterile, white to off-white lyophilized powder, and dibasic sodium phosphate anhydrous (1.11 mg), monobasic sodium phosphate dihydrate (1.11 mg), polysorbate 80 (0.074 mg), and sucrose (59.2 mg). </p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="S12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Peginterferon alfa-2b is a pleiotropic cytokine; the mechanism by which it exerts its effects in patients with melanoma is unknown.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="S12.3"></a><a name="section-11.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">The pharmacokinetics was studied in 32 patients receiving adjuvant therapy for melanoma with SYLATRON according to the recommended dose and schedule (6 mcg/kg/week for 8 doses, followed by 3 mcg/kg/week thereafter). At a dose of 6 mcg/kg/week once weekly, the geometric mean C<span class="Sub">max</span> was 4.4 ng/mL (CV 51%) and the geometric mean AUC<span class="Sub">tau</span> was 430 ng∙hr/mL (CV 35%) at week 8. The mean terminal half-life was approximately 51 hours (CV 18%). The mean accumulation from week 1 to week 8 was 1.7. After administration of 3 mcg/kg/week once weekly, the mean geometric C<span class="Sub">max</span> was 2.5 ng/mL (CV 33%) and the geometric mean AUC<span class="Sub">tau</span> was 228 ng∙hr/mL (CV 24%) at week 4. The mean terminal half-life was approximately 43 hours (CV 19%).</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.1"></a><p></p>
<p class="First"><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>:</span></p>
<p>Renal clearance accounts for approximately 30% of total peginterferon alfa-2b clearance. The effect of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> on the pharmacokinetics of peginterferon alfa-2b was studied in 24 subjects with normal or <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> after a single 4.5 mcg/kg dose. Compared to subjects with normal renal function (CLcr &gt; 80 mL/min/1.73 m<span class="Sup">2</span>), the geometric mean AUC<span class="Sub">last</span> to peginterferon alfa-2b increased by 1.4-fold in subjects with moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CLcr 30 to 50 mL/min/1.73m<span class="Sup">2</span>) and 2.1-fold in subjects with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CLcr &lt; 30 mL/min/1.73m<span class="Sup">2</span>) or ESRD requiring dialysis <span class="Italics">[see <a href="#S8.7">Use in Specific Populations (8.7)</a>]</span>.</p>
<p>No clinically meaningful amounts of peginterferon alfa-2b were removed during hemodialysis following a single 1 mcg/kg dose in subjects with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.2"></a><p></p>
<p class="First"><span class="Bold Italics">Drug Interactions:</span></p>
<p>Peginterferon alfa-2b inhibits CYP1A2 and CYP2D6 activity. In a drug interaction study, healthy subjects received a dose of 200 mg of caffeine (CYP1A2 substrate), 2 mg of midazolam (CYP3A4 substrate), 500 mg of tolbutamide (CYP2C9 substrate), or 50 mg of desipramine (CYP2D6 substrate) before and after two doses of SYLATRON administered subcutaneously at a dose of 3 mcg/kg. The geometric mean AUC<span class="Sub">last</span> was increased by 36% for caffeine and 30% for desipramine when coadministered with SYLATRON compared to caffeine or desipramine administered alone. No clinically meaningful changes in CYP2C9 activity and CYP3A4 activity were observed. <span class="Italics">[See <a href="#S7">Drug Interactions (7)</a>.]</span></p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="S13"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="S13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.1.1"></a><p></p>
<p class="First"><span class="Bold Italics">Carcinogenesis and Mutagenesis:</span></p>
<p>SYLATRON has not been tested for its carcinogenic potential. Neither peginterferon alfa-2b nor its components, interferon or methoxypolyethylene glycol, caused damage to DNA when tested in the standard battery of mutagenesis assays, in the presence and absence of metabolic activation.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.1.2"></a><p></p>
<p class="First"><span class="Bold Italics">Impairment of Fertility:</span></p>
<p>SYLATRON may impair human fertility. <span class="product-label-link" type="condition" conceptid="196168" conceptname="Irregular periods">Irregular menstrual cycles</span> were observed in female cynomolgus monkeys given subcutaneous injections of 4239 mcg/m<span class="Sup">2</span> peginterferon alfa-2b alone every other day for 1 month (approximately 72 to 144 times the recommended weekly human dose based upon body surface area). These effects included transiently decreased serum levels of estradiol and progesterone, suggestive of <span class="product-label-link" type="condition" conceptid="4144685" conceptname="Anovulation">anovulation</span>. Normal menstrual cycles and serum hormone levels resumed in these animals 2 to 3 months following cessation of peginterferon alfa-2b treatment. Every other day dosing with 262 mcg/m<span class="Sup">2</span> (approximately 3.5 to 7 times the recommended weekly human dose) had no effects on cycle duration or reproductive hormone status. The effects of SYLATRON on male fertility have not been studied.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="S14"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">The safety and effectiveness of SYLATRON were evaluated in an open-label, multicenter, randomized (1:1) study conducted in 1256 patients with surgically resected, AJCC Stage III melanoma within 84 days of regional lymph node dissection. Patients were randomized to observation (no therapy) (n=629) or to SYLATRON (n=627) at a dose of 6 mcg/kg by subcutaneous injection once weekly for 8 doses followed by a 3 mcg/kg subcutaneous injection once weekly for a period of up to 5 years total treatment. The dose of SYLATRON was adjusted to maintain an ECOG Performance Status of 0 to 1.</p>
<p>The median age of the population was 50 years with 11% of patients 65 years or older, and 42% were female. Forty percent of the study population had microscopic, nonpalpable nodal involvement and 59% had clinically palpable nodes prior to lymphadenectomy. A total of 54% of subjects had one pathologically positive lymph node, 34% had 2 to 4 positive nodes, and 12% had 5 or more. Most subjects had no second primary lesion (98%). Ulceration of the primary lesion was present in 30% of subjects (52% had no ulceration of the primary lesion, and the status was missing/unknown for 18% of subjects). The most common sites were the trunk (43%) or the leg (32%). Eighty-four percent had an International Prognostic Index (IPI) score of 0 and 16% had an IPI score of 1. The main outcome measure was relapse-free survival (RFS), defined as the time from randomization to the earliest date of any relapse (local, regional, in-transit, or distant), or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> from any cause. Secondary outcome measures included overall survival.</p>
<p>Patients in the SYLATRON arm received 6 mcg/kg/week for a median of 8.0 weeks. Less than 1% of patients took longer than 9 weeks to complete the 6 mcg/kg/week dosing regimen. Approximately one-third (36%) of patients required dose reductions and 29% of patients required a dose delay, with an average delay of 1.2 weeks, during the initial 8 weeks of SYLATRON. Ninety-four patients (16%) did not continue on to the 3 mcg/kg/week dosing regimen.</p>
<p>Patients who continued on SYLATRON after the initial 8 doses, received 3 mcg/kg/week for a median duration of treatment of 14.3 months. Approximately half (52%) of the patients underwent dose reductions and 70% required dose delays (average delay 2.2 weeks).</p>
<p>Based on 696 RFS events, determined by the Independent Review Committee, median RFS was 34.8 months (95% CI: 26.1, 47.4) and 25.5 months (95% CI: 19.6, 30.8) in the SYLATRON and observation arms, respectively. The estimated hazard ratio for RFS was 0.82 (95% CI: 0.71, 0.96; unstratified log-rank p =0.011) in favor of SYLATRON. Figure 1 shows the Kaplan-Meier curves of RFS.</p>
<table class="Noautorules" width="100%">
<col align="center" valign="top" width="100%">
<tbody class="Headless">
<tr><td align="center"><span class="Bold">FIGURE 1: Kaplan-Meier Curves for Relapse-Free Survival</span></td></tr>
<tr><td align="center"><img alt="Figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3874c95c-092e-4cd5-b104-6ed2bc391b0e&amp;name=sylatron-5ml-01.jpg"></td></tr>
</tbody>
</table>
<p>There was no statistically significant difference in survival between the SYLATRON and the observation arms. Based on 525 <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span>, the estimated hazard ratio of SYLATRON versus observation was 0.98 (95% CI: 0.82, 1.16).</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="S16"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<table width="75%">
<col align="left" valign="top" width="75%">
<col align="center" valign="top" width="25%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left">Each SYLATRON Package Contains:</th>
<th class="Rrule" align="center"></th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">A box containing one 200 mcg per vial of SYLATRON powder and one 5 mL vial of Sterile Water for Injection, USP, 2 B-D Safety Lok syringes with a safety sleeve and 2 alcohol swabs.</td>
<td class="Rrule" align="center">(NDC 0085-4347-01)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">A box containing one 300 mcg per vial of SYLATRON powder and one 5 mL vial of Sterile Water for Injection, USP, 2 B-D Safety Lok syringes with a safety sleeve and 2 alcohol swabs.</td>
<td class="Rrule" align="center">(NDC 0085-4348-01)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">A box containing one 600 mcg per vial of SYLATRON powder and one 5 mL vial of Sterile Water for Injection, USP, 2 B-D Safety Lok syringes with a safety sleeve and 2 alcohol swabs.</td>
<td class="Rrule" align="center">(NDC 0085-4349-01)</td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="44425-7">
<a name="section-14.1"></a><p></p>
<p class="First"><span class="Bold Italics">Storage:</span></p>
<p>SYLATRON should be stored at 25°C (77°F); excursions permitted to 15°-30°C (59-86°F) [see USP Controlled Room Temperature]. <span class="Bold">DO NOT FREEZE.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="S17"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">See FDA-approved patient labeling (<a href="#IFU">Instructions for Use</a> and <a href="#MG">Medication Guide</a>).</p>
<ul>
<li>Advise patients that SYLATRON may be administered with antipyretics at bedtime to minimize common "flu-like" symptoms (including <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle aches</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span>).</li>
<li>Advise patients to maintain hydration if experiencing "flu-like" symptoms.</li>
<li>Advise patients and their caregivers to immediately report any symptoms of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span> to their healthcare provider during treatment and up to 6 months after the last dose.</li>
<li>Use SYLATRON during pregnancy only if the potential benefit justifies the potential risk to the fetus <span class="Italics">[see <a href="#S8.1">Use in Specific Populations (8.1)</a>]</span>.</li>
<li>Instruct patients to not re-use or share syringes and needles.</li>
<li>Instruct patients on proper disposal of vials, syringes and needles.</li>
<li>Advise patients that the Sterile Water for Injection vials supplied contain an excess amount of diluent and only 0.7 mL should be withdrawn to reconstitute SYLATRON. Discard the unused portion of sterile water. Do not save or reuse.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16"></a><p></p>
<p class="First">Manufactured by: Schering Corporation, a subsidiary of<br><span class="Bold">MERCK &amp; CO., INC., </span>Whitehouse Station, NJ 08889, USA</p>
<p>Revised: 5/2015</p>
<p>For patent information: www.merck.com/product/patent/home.html</p>
<p>BD and Safety-Lok are registered trademarks of Becton, Dickinson and Company.</p>
<p>Copyright © 2011 Merck Sharp &amp; Dohme Corp., a subsidiary of <span class="Bold">Merck &amp; Co., Inc.</span><br>All rights reserved.</p>
<p>uspi-mk4031-pwi-5ml-1505r002</p>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="MG"></a><a name="section-17"></a><p></p>
<h1>MEDICATION GUIDE</h1>
<p class="First"><span class="Bold">SYLATRON™</span> (SY-LA-TRON)<br>(Peginterferon alfa-2b)</p>
<p>Read this Medication Guide before you start taking SYLATRON, and each time you get a refill. There may be new information. This Medication Guide does not take the place of talking with your healthcare provider about your medical condition or your treatment.</p>
<p><a name="important"></a><span class="Bold">What is the most important information I should know about SYLATRON?</span></p>
<p><span class="Bold">SYLATRON can cause serious mental health problems which can lead to <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>. </span></p>
<p>SYLATRON may cause you to develop mood or behavior problems that may get worse during treatment with SYLATRON or after your last dose. Call your healthcare provider right away if you, your family, or caregiver notice any of the following:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span> (getting upset easily)</li>
<li><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> (feeling low, feeling bad about yourself, or feeling hopeless)</li>
<li><span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressive behavior</span>, being angry or violent </li>
<li>thoughts of hurting yourself or others, or <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span></li>
</ul>
<p>Former drug addicts may <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> back into <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">drug addiction</span> or <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.</p>
<p>If you have these symptoms, your healthcare provider should carefully monitor you during treatment with SYLATRON and for 6 months after your last dose.</p>
<p>If symptoms get worse or become severe and continue, your healthcare provider may tell you to stop taking SYLATRON permanently. These signs or symptoms may not go away after you stop taking SYLATRON.</p>
<p>See "<span class="Bold"><a href="#possible">What are the possible side effects of SYLATRON?</a></span>" for more information about side effects.</p>
<p><span class="Bold">What is SYLATRON?</span></p>
<p>SYLATRON is a prescription medicine that is used to prevent malignant melanoma (a kind of skin cancer) from coming back after it has been removed by surgery. SYLATRON should be started within 84 days of surgery to remove lymph nodes containing cancer.</p>
<p>It is not known if SYLATRON is safe and effective in children less than 18 years of age.</p>
<p><span class="Bold">Who should not take SYLATRON?</span></p>
<p>Do not take SYLATRON:</p>
<ul>
<li>if you have had a serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to peginterferon alfa-2b or to interferon alfa-2b</li>
<li>if you have certain types of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span></li>
<li>if you have severe <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver damage</span></li>
</ul>
<p><span class="Bold">What should I tell my healthcare provider before taking SYLATRON?</span></p>
<p>Before you take SYLATRON, tell your healthcare provider about all of your health problems, including if you:</p>
<ul>
<li>are being treated for a mental illness or had treatment in the past for mental illness, including <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or thoughts of hurting yourself or others or <span class="product-label-link" type="condition" conceptid="4219484" conceptname="Suicide attempt">suicide attempts</span>. See "<span class="Bold"><a href="#important">What is the most important information I should know about SYLATRON?</a></span>"</li>
<li>have <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver damage</span> from drugs or cirrhosis or other liver disease</li>
<li>have kidney problems or are receiving kidney dialysis treatment</li>
<li>have ever been addicted to drugs or alcohol</li>
<li>have or had an overactive or underactive thyroid gland</li>
<li>have <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span></li>
<li>have any other medical problem(s)</li>
<li>are pregnant or plan to become pregnant. It is not known if SYLATRON will harm your unborn baby.</li>
<li>are breastfeeding or plan to breastfeed. You and your healthcare provider should decide if you should use SYLATRON or breastfeed. You should not do both.</li>
</ul>
<p>Tell your healthcare provider about all the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements.</p>
<p>SYLATRON and certain other medicines may affect each other and cause side effects.</p>
<p>Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist each time you get a new medicine.</p>
<p>You should not start a new medicine before your talk with the healthcare provider who prescribes you SYLATRON.</p>
<p><span class="Bold">How should I take SYLATRON?</span></p>
<ul>
<li>Take SYLATRON exactly as your healthcare provider tells you to. Your healthcare provider will tell you how much SYLATRON to take and when to take it.</li>
<li>Do not take more than your prescribed dose. Call your healthcare provider right away if you take too much SYLATRON.</li>
<li>Inject SYLATRON one time each week unless instructed differently by your healthcare provider. Call your healthcare provider for instructions if you miss a dose. </li>
<li>SYLATRON is given as an injection under your skin (subcutaneous injection). Your healthcare provider should show you how to prepare and measure your dose of SYLATRON, and how to inject yourself before you use SYLATRON for the first time.</li>
<li>Expect to get "flu-like" symptoms when taking SYLATRON. To help reduce flu-like symptoms: 							<ul class="Circle">
<li>You should take 500 mg to 1,000 mg of acetaminophen 30 minutes before your first dose of SYLATRON.</li>
<li>Follow your healthcare provider's instructions about taking acetaminophen before future doses of SYLATRON.</li>
<li>Inject SYLATRON at bedtime to help reduce flu-like symptoms.</li>
<li>Drink plenty of fluids.</li>
</ul>
</li>
</ul>
<p>Your healthcare provider should do blood tests before you start and regularly during treatment with SYLATRON.</p>
<p>Your healthcare provider will monitor you while taking SYLATRON. Based on this monitoring, your healthcare provider may:</p>
<ul>
<li>Keep your prescribed dose the same;</li>
<li>Reduce your prescribed dose;</li>
<li>Tell you to skip a dose or doses; or</li>
<li>Tell you to stop taking SYLATRON permanently.</li>
</ul>
<p><a name="possible"></a><span class="Bold">What are the possible side effects of SYLATRON?</span></p>
<p>SYLATRON can cause serious side effects or worsen existing problems, including:</p>
<p>See "<span class="Bold"><a href="#important">What is the most important information I should know about SYLATRON?</a></span>".</p>
<ul>
<li>
<span class="Bold">Heart problems. </span>Signs and symptoms can include: 							<ul class="Circle">
<li>fast heart rate or abnormal heart beat</li>
<li>trouble breathing or <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span></li>
</ul>
</li>
<li>
<span class="Bold">Serious eye problems. </span>Symptoms can include: 							<ul class="Circle">
<li>decrease in vision</li>
<li><span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span></li>
</ul>
</li>
<li>
<span class="Bold">Severe or worsening liver problems. </span>Symptoms can include: 							<ul class="Circle">
<li>yellowing of your skin or the white part of your eyes</li>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your stomach area (abdomen)</li>
</ul>
</li>
<li>
<span class="Bold">Thyroid problems. </span>Signs and symptoms can include: 							<ul class="Circle">
<li>problems concentrating</li>
<li><span class="product-label-link" type="condition" conceptid="4276665" conceptname="Feels cold">feeling cold</span> or hot all of the time</li>
<li>weight changes</li>
</ul>
</li>
<li>
<span class="Bold">High blood sugar (<span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>). </span>Signs and symptoms can include: 							<ul class="Circle">
<li><span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">increased thirst</span></li>
<li>urinating more often than normal</li>
<li><span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span></li>
<li>your breath smells like fruit</li>
</ul>
</li>
</ul>
<p><span class="Bold">Call your healthcare provider right away if you have any of these serious side effects.</span></p>
<p><span class="Bold">The most common side effects of SYLATRON include:</span></p>
<ul>
<li>flu-like symptoms, which may include <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span>, muscle or <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint aches</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, or loss of appetite</li>
<li>feeling sad or depressed</li>
<li><span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, or <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> around the injection site</li>
<li>changes in blood tests measuring how your liver works</li>
</ul>
<p>These are not all of the possible side effects of SYLATRON. For more information, ask your healthcare provider. </p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1–800–FDA–1088.</p>
<p>You may also report side effects to Schering Corporation at 1-800-526-4099.</p>
<p><span class="Bold">How should I store SYLATRON?</span></p>
<ul>
<li>Store SYLATRON vials in the carton at 59°F to 86°F (15°C to 30°C).</li>
<li>After mixing, use SYLATRON right away or store it in the refrigerator for no longer than 24 hours at 36°F to 46°F (2°C to 8°C).</li>
<li>Do not freeze SYLATRON.</li>
</ul>
<p>Keep SYLATRON and all medicines out of the reach of children.</p>
<p><span class="Bold">General information about the safe and effective use of SYLATRON</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use SYLATRON for a condition for which it was not prescribed. Do not give SYLATRON to other people, even if they have the same symptoms that you have. It may harm them.</p>
<p>This Medication Guide summarizes the most important information about SYLATRON. If you would like more information, talk with your healthcare provider. You can ask your healthcare provider for information about SYLATRON that is written for healthcare professionals.</p>
<p>For more information, go to www.SYLATRON.com or call 1-800-526-4099.</p>
<p><span class="Bold">What are the ingredients in SYLATRON?</span></p>
<p><span class="Bold">Active ingredient: </span>peginterferon alfa-2b</p>
<p><span class="Bold">Inactive ingredients:</span> dibasic sodium phosphate anhydrous, monobasic sodium phosphate dihydrate, polysorbate 80, sucrose, sterile water for injection is supplied as a diluent.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-18"></a><p></p>
<p class="First">This Medication Guide has been approved by the U.S. Food and Drug Administration.</p>
<p>Manufactured by: Schering Corporation, a subsidiary of<br><span class="Bold">MERCK &amp; CO., INC., </span>Whitehouse Station, NJ 08889, USA</p>
<p>Revised: May 2015</p>
<p>For patent information: www.merck.com/product/patent/home.html</p>
<p>Copyright © 2011 Merck Sharp &amp; Dohme Corp.,<br>a subsidiary of <span class="Bold">Merck &amp; Co., Inc.</span><br>All rights reserved.</p>
<p>usmg-mk4031-pwi-1505r011</p>
</div>
<div class="Section" data-sectionCode="59845-8">
<a name="IFU"></a><a name="section-19"></a><p></p>
<h1>Instructions for Use</h1>
<p class="First">SYLATRON<span class="Bold">™</span> (SY-LA-TRON)<br>(peginterferon alfa-2b)<br>for injection<br>Powder for Injection</p>
<p>Be sure that you read, understand and follow these instructions before injecting SYLATRON. Your healthcare provider should show you how to prepare, measure, and inject SYLATRON properly before you use it for the first time. Ask your healthcare provider if you have any questions.</p>
<p>Before starting, collect all of the supplies that you will need to use for preparing and injecting SYLATRON. For each injection you will need a SYLATRON vial package that contains:</p>
<ul>
<li>1 vial of SYLATRON powder</li>
<li>1 vial of sterile water for injection (diluent). The vial contains an excess amount of sterile water (5 mL). You will only need to withdraw 0.7 mL to prepare your single dose.</li>
<li>2 single-use disposable syringes (BD Safety Lok syringes with a safety sleeve)</li>
<li>2 alcohol swabs</li>
</ul>
<p>You will also need:</p>
<ul>
<li>1 cotton ball or gauze</li>
<li>1 sharps disposal container to throw away (dispose of) used syringes, needles, and vials. See "<a href="#ifuhow">How should I dispose of used syringes, needles, and vials?</a>" at the end of this Instructions for Use.</li>
</ul>
<p><span class="Bold">Important:</span></p>
<ul>
<li><span class="Bold">Do not re-use or share syringes and needles.</span></li>
<li>The vial of mixed SYLATRON should be used right away. Do not mix more than 1 vial of SYLATRON at a time. If you do not use the vial of the prepared solution right away, store it in a refrigerator and use within 24 hours. See the end of this Instructions for Use for information about "<a href="#store">How should I store SYLATRON?</a>"</li>
<li>Make sure you have the right syringe and needle to use with SYLATRON. Your healthcare provider should tell you what syringes and needles to use to inject SYLATRON.</li>
</ul>
<p><span class="Bold">How should I prepare a dose of SYLATRON?</span></p>
<p>Before you inject SYLATRON, the powder must be mixed with 0.7 mL of the sterile water for injection (diluent) that comes in the SYLATRON vial package.</p>
<ol>
<li>Find a clean, well-lit, flat work surface.</li>
<li>Get 1 of your SYLATRON vial packages. Check the date printed on the SYLATRON carton. Make sure that the expiration date has not passed. Do not use your SYLATRON vial packages if the expiration date has passed. The medicine in the SYLATRON vial should look like a white to off-white tablet that is whole, or in pieces, or powdered.<br>If you have already mixed the SYLATRON solution and stored it in the refrigerator, take it out of the refrigerator before use and allow the solution to come to room temperature.</li>
<li>Wash your hands well with soap and water, rinse and towel dry (See <a href="#figa">Figure A</a>). Keep your work area, your hands, and injection site clean to decrease the risk of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.<br><div class="Figure">
<a name="figa"></a><img alt="Figure A" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3874c95c-092e-4cd5-b104-6ed2bc391b0e&amp;name=sylatron-5ml-02.jpg"><p class="MultiMediaCaption">Figure A</p>
</div>
<br>The disposable syringes have needles that are already attached and cannot be removed. Each syringe has a clear plastic safety sleeve that is pulled over the needle for disposal after use. The safety sleeve should remain tight against the flange while using the syringe and moved over the needle only when ready for disposal. (See <a href="#figb">Figure B</a>)<br><div class="Figure">
<a name="figb"></a><img alt="Figure B" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3874c95c-092e-4cd5-b104-6ed2bc391b0e&amp;name=sylatron-5ml-03.jpg"><p class="MultiMediaCaption">Figure B</p>
</div>
</li>
<li>Remove the protective wrapper from one of the syringes provided. Use the syringe for steps 4 through 15. Make sure that the syringe safety sleeve is sitting against the flange. (See <a href="#figb">Figure B</a>)</li>
<li>Remove the protective plastic cap from the tops of both the sterile water for injection (diluent) and the SYLATRON vials (See <a href="#figc">Figure C</a>). Clean the rubber stopper on the top of both vials with an alcohol swab.<br><div class="Figure">
<a name="figc"></a><img alt="Figure C" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3874c95c-092e-4cd5-b104-6ed2bc391b0e&amp;name=sylatron-5ml-04.jpg"><p class="MultiMediaCaption">Figure C</p>
</div>
</li>
<li>Carefully remove the protective cap straight off of the needle to avoid damaging the needle point.</li>
<li>Fill the syringe with air by pulling back on the plunger to 0.7 mL. (See <a href="#figd">Figure D</a>)<br><div class="Figure">
<a name="figd"></a><img alt="Figure D" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3874c95c-092e-4cd5-b104-6ed2bc391b0e&amp;name=sylatron-5ml-05.jpg"><p class="MultiMediaCaption">Figure D</p>
</div>
</li>
<li>Hold the diluent vial upright. Do not touch the cleaned top of the vial with your hands.<br><ul class="Disc">
<li>Push the needle through the center of the rubber stopper of the diluent vial. (See <a href="#fige">Figure E</a>)</li>
<li>Slowly inject all the air from the syringe into the air space above the diluent in the vial. (See <a href="#figf">Figure F</a>) 								<table class="Noautorules" width="100%">
<col align="center" valign="top" width="50%">
<col align="center" valign="top" width="50%">
<tbody class="Headless"><tr>
<td align="center">
<p class="First"><a name="fige"></a><img alt="Figure E" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3874c95c-092e-4cd5-b104-6ed2bc391b0e&amp;name=sylatron-5ml-06.jpg"></p>
<br><span class="Bold">Figure E</span>
</td>
<td align="center">
<p class="First"><a name="figf"></a><img alt="Figure F" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3874c95c-092e-4cd5-b104-6ed2bc391b0e&amp;name=sylatron-5ml-07.jpg"></p>
<br><span class="Bold">Figure F</span>
</td>
</tr></tbody>
</table>
</li>
</ul>
</li>
<li>Turn the vial upside down and make sure the tip of the needle is in the liquid. 							<ul class="Circle"><li>Important: The sterile water for injection vial contains an excess amount of sterile water (5 mL). <span class="Bold">You will only need to withdraw 0.7 mL to prepare your single dose.</span>
</li></ul>
</li>
<li>Withdraw only 0.7 mL of diluent by pulling the plunger back to the 0.7 mL mark on the side of the syringe. (See <a href="#figg">Figure G</a>)<br><div class="Figure">
<a name="figg"></a><img alt="Figure G" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3874c95c-092e-4cd5-b104-6ed2bc391b0e&amp;name=sylatron-5ml-08.jpg"><p class="MultiMediaCaption">Figure G</p>
</div>
</li>
<li>With the needle still inserted in the vial, check the syringe for air bubbles. 							<ul class="Disc">
<li>If there are any air bubbles, gently tap the syringe with your finger until the air bubbles rise to the top of the syringe.</li>
<li>Slowly push the plunger up to remove the air bubbles.</li>
<li>If you push diluent back into the vial, slowly pull back on the plunger to draw the correct amount of diluent back into the syringe.</li>
</ul>
</li>
<li>Remove the needle from the vial (See <a href="#figh">Figure H</a>). Do not let the syringe touch anything.<br><div class="Figure">
<a name="figh"></a><img alt="Figure H" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3874c95c-092e-4cd5-b104-6ed2bc391b0e&amp;name=sylatron-5ml-09.jpg"><p class="MultiMediaCaption">Figure H</p>
</div>
</li>
<li>Throw away the diluent that is left over in the vial. Do not save any leftover diluent or use it again. See "<a href="#ifuhow">How should I dispose of used syringes, needles, and vials?</a>" at the end of this Instructions for Use.</li>
<li>Insert the needle through the center of the rubber stopper of the SYLATRON powder vial. Do not touch the cleaned rubber stopper. 							<ul class="Disc">
<li>Place the needle tip, at an angle, against the side of the vial. (See <a href="#figi">Figure I</a>)</li>
<li>Slowly push the plunger down to inject the 0.7 mL diluent. The stream of diluent should run down the side of the vial.</li>
<li>To prevent bubbles from forming, do not aim the stream of diluent directly on the medicine in the bottom of the vial.<br><div class="Figure">
<a name="figi"></a><img alt="Figure I" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3874c95c-092e-4cd5-b104-6ed2bc391b0e&amp;name=sylatron-5ml-10.jpg"><p class="MultiMediaCaption">Figure I</p>
</div>
</li>
</ul>
</li>
<li>Remove the needle from the vial. 							<ul class="Disc"><li>Firmly grasp the safety sleeve and pull it over the exposed needle until you hear a click (See <a href="#figj">Figure J</a>). The green stripe on the safety sleeve will completely cover the red stripe on the needle. Dispose of the syringe, needle, and vial in the sharps disposal container. See "<a href="#ifuhow">How should I dispose of used syringes, needles, and vials?</a>" at the end of this Instructions for Use.<br><div class="Figure">
<a name="figj"></a><img alt="Figure J" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3874c95c-092e-4cd5-b104-6ed2bc391b0e&amp;name=sylatron-5ml-11.jpg"><p class="MultiMediaCaption">Figure J</p>
</div>
</li></ul>
</li>
<li>Gently swirl the vial in a gentle circular motion, until the SYLATRON is completely dissolved (mixed together). (See <a href="#figk">Figure K</a>) 							<ul class="Disc">
<li>Do not shake the vial. If any powder remains undissolved in the vial, gently turn the vial upside down until all of the powder is dissolved.</li>
<li>The solution may look cloudy or bubbly for a few minutes. If air bubbles form, wait until the solution settles and all bubbles rise to the top.<br><div class="Figure">
<a name="figk"></a><img alt="Figure K" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3874c95c-092e-4cd5-b104-6ed2bc391b0e&amp;name=sylatron-5ml-12.jpg"><p class="MultiMediaCaption">Figure K</p>
</div>
</li>
</ul>
</li>
<li>After the SYLATRON completely dissolves, the solution should be clear, colorless and without particles. It is normal to see a ring of foam or bubbles on the surface. 							<ul class="Disc"><li>Do not use the mixed solution if you see particles in it, or it is not clear and colorless. Dispose of the syringe and needle in the sharps disposal container. See the section "<a href="#ifuhow">How should I dispose of used syringes, needles, and vials?</a>" at the end of this Instructions for Use. Then, repeat steps 1 through 17 with a new vial of SYLATRON and diluent to prepare a new syringe.</li></ul>
</li>
<li>After the SYLATRON powder completely dissolves, clean the rubber stopper again with an alcohol swab before you withdraw your dose.</li>
<li>Unwrap the second syringe provided. You will use it to give yourself the injection. 							<ul class="Disc">
<li>Carefully remove the protective cap from the needle. Fill the syringe with air by pulling the plunger to the number on the side of the syringe (mL) that matches your prescribed dose. (See <a href="#figl">Figure L</a>)<br><div class="Figure">
<a name="figl"></a><img alt="Figure L" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3874c95c-092e-4cd5-b104-6ed2bc391b0e&amp;name=sylatron-5ml-13.jpg"><p class="MultiMediaCaption">Figure L</p>
</div>
</li>
<li>Hold the SYLATRON vial upright. Do not touch the cleaned top of the vial with your hands. (See <a href="#figm">Figure M</a>)<br><div class="Figure">
<a name="figm"></a><img alt="Figure M" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3874c95c-092e-4cd5-b104-6ed2bc391b0e&amp;name=sylatron-5ml-14.jpg"><p class="MultiMediaCaption">Figure M</p>
</div>
</li>
<li>Insert the needle into the vial containing the SYLATRON solution. Inject the air into the center of the vial. (See <a href="#fign">Figure N</a>)<br><div class="Figure">
<a name="fign"></a><img alt="Figure N" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3874c95c-092e-4cd5-b104-6ed2bc391b0e&amp;name=sylatron-5ml-15.jpg"><p class="MultiMediaCaption">Figure N</p>
</div>
</li>
</ul>
</li>
<li>Turn the SYLATRON vial upside down. Be sure the tip of the needle is in the SYLATRON solution. 							<ul class="Disc"><li>Hold the vial and syringe with one hand. Be sure the tip of the needle is in the SYLATRON solution. With the other hand, slowly pull the plunger back to fill the syringe with the exact amount of SYLATRON into the syringe your healthcare provider told you to use. (See <a href="#figo">Figure O</a>)<br><div class="Figure">
<a name="figo"></a><img alt="Figure O" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3874c95c-092e-4cd5-b104-6ed2bc391b0e&amp;name=sylatron-5ml-16.jpg"><p class="MultiMediaCaption">Figure O</p>
</div>
</li></ul>
</li>
<li>Check for air bubbles in the syringe. If you see any air bubbles, hold the syringe with the needle pointing up. Gently tap the syringe until the air bubbles rise. Then, slowly push the plunger up to remove any air bubbles. If you push solution into the vial, slowly pull back on the plunger again to draw the correct amount of SYLATRON back into the syringe. When you are ready to inject the medicine, remove the needle from the vial. (See <a href="#figp">Figure P</a>)<br><div class="Figure">
<a name="figp"></a><img alt="Figure P" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3874c95c-092e-4cd5-b104-6ed2bc391b0e&amp;name=sylatron-5ml-17.jpg"><p class="MultiMediaCaption">Figure P</p>
</div>
</li>
</ol>
<p><span class="Bold">How should I choose a site for injection?</span></p>
<p>The best sites for giving yourself an injection are those areas with a layer of fat between the skin and muscle, like your thigh, the outer surface of your upper arm, and abdomen (See <a href="#figq">Figure Q</a>). Do not inject yourself in the area near your navel or waistline. If you are very thin, you should only use the thigh or outer surface of the arm for injection.</p>
<div class="Figure">
<a name="figq"></a><img alt="Figure Q" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3874c95c-092e-4cd5-b104-6ed2bc391b0e&amp;name=sylatron-5ml-18.jpg"><p class="MultiMediaCaption">Figure Q</p>
</div>
<p>You should use a different site each time you inject SYLATRON to help avoid soreness at any one site. Do not inject SYLATRON solution into an area where the skin is irritated, red, bruised, infected or has <span class="product-label-link" type="condition" conceptid="4050007" conceptname="Scar">scars</span>, stretch marks, or lumps.</p>
<p><span class="Bold">How should I inject a dose of SYLATRON?</span></p>
<dl>
<dt>22. </dt>
<dd>Clean the skin where the injection is to be given with an alcohol swab. Wait for the area to dry.<ul class="Disc"><li>Make sure the safety sleeve of the syringe is pushed firmly against the syringe flange so that the needle is fully exposed. (See <a href="#figb">Figure B</a>)</li></ul>
</dd>
<dt>23. </dt>
<dd>With one hand, pinch a fold of skin. With your other hand, pick up the syringe and hold it like a pencil. 							<ul class="Disc">
<li>Insert the needle into the pinched skin at a 45- to 90-degree angle with a quick dart-like motion. (See <a href="#figr">Figure R</a>)<br><div class="Figure">
<a name="figr"></a><img alt="Figure R" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3874c95c-092e-4cd5-b104-6ed2bc391b0e&amp;name=sylatron-5ml-19.jpg"><p class="MultiMediaCaption">Figure R</p>
</div>
</li>
<li>After the needle is inserted, remove the hand that you used to pinch your skin. Use it to hold the syringe barrel.</li>
<li>Pull the plunger of the syringe back very slightly.</li>
<li>
<span class="Bold">If no blood is present in the syringe</span>, inject the medicine by gently pressing the plunger all the way down the syringe barrel, until the syringe is empty.</li>
<li>
<span class="Bold">If blood comes into the syringe</span>, the needle has entered a blood vessel. Do not inject. 								<ul class="Circle">
<li>Withdraw the needle and dispose of the syringe and needle in the sharps disposal container. (See the section "<a href="#ifuhow">How should I dispose of used syringes, needles, and vials?</a>" at the end of this Instructions for Use.)</li>
<li>If there is <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, cover the injection site with a bandage.</li>
<li>Then, repeat steps 1 through 23 with a new vial of SYLATRON and diluent to prepare a new syringe, and inject the medicine at a new site.</li>
</ul>
</li>
</ul>
</dd>
<dt>24. </dt>
<dd>When the syringe is empty, pull the needle out of the skin. 							<ul class="Disc">
<li>Place a cotton ball or gauze over the injection site and press for several seconds. Do not massage the injection site.</li>
<li>If there is <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, cover it with a bandage.</li>
</ul>
</dd>
<dt>25. </dt>
<dd>After injecting your dose: 							<ul class="Disc"><li>Firmly grasp the safety sleeve and pull it over the exposed needle until you hear a click, and the green stripe on the safety sleeve covers the red stripe on the needle. (See <a href="#figs">Figure S</a>)<br><div class="Figure">
<a name="figs"></a><img alt="Figure S" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3874c95c-092e-4cd5-b104-6ed2bc391b0e&amp;name=sylatron-5ml-20.jpg"><p class="MultiMediaCaption">Figure S</p>
</div>
</li></ul>
</dd>
<dt>26. </dt>
<dd>Dispose of the used syringes, needles, and vials in the sharps disposal container. (See "<a href="#ifuhow">How should I dispose of used syringes, needles, and vials?</a>" below.)</dd>
</dl>
<p><a name="ifuhow"></a><span class="Bold">How should I dispose of used syringes, needles, and vials?</span></p>
<ul>
<li>Put your used syringes and needles in a FDA-cleared sharps disposal container right away after use. <span class="Bold">Do not throw away (dispose of) loose syringes and needles in your household trash</span>. </li>
<li>If you do not have a FDA-cleared sharps disposal container, you may use a household container that is: 							<ul class="Circle">
<li>made of a heavy-duty plastic,</li>
<li>can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out,</li>
<li>upright and stable during use, </li>
<li>leak-resistant, and</li>
<li>properly labeled to warn of hazardous waste inside the container.</li>
</ul>
</li>
<li>When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away used syringes and needles. For more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDA's website at: http://www.fda.gov/safesharpsdisposal.</li>
<li>Do not dispose of your used sharps disposal container in your household trash unless your community guidelines permit this. Do not recycle your used sharps disposal container.</li>
</ul>
<p>Always keep the sharps disposal container out of the reach of children.</p>
<p><a name="store"></a><span class="Bold">How should I store SYLATRON?</span></p>
<ul>
<li>Before mixing, store SYLATRON vials at 59°F to 86°F (15°C to 30°C).</li>
<li>After mixing, use SYLATRON right away or store it in the refrigerator for up to 24 hours between 36°F to 46°F (2°C to 8°C). Throw away any mixed SYLATRON that is not used within 24 hours.</li>
<li>Do not freeze SYLATRON.</li>
<li>Keep SYLATRON away from heat.</li>
</ul>
<p><span class="Bold">Keep SYLATRON and all medicines out of the reach of children.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-20"></a><p></p>
<p class="First">This Instructions for Use has been approved by the U.S. Food and Drug Administration.</p>
<p>Manufactured by: Schering Corporation, a subsidiary of <br><span class="Bold">MERCK &amp; CO., INC.,</span> Whitehouse Station, NJ 08889, USA</p>
<p>Revised: August 2014</p>
<p>For patent information: www.merck.com/product/patent/home.html</p>
<p>Copyright © 2011 Merck Sharp &amp; Dohme Corp., a subsidiary of <span class="Bold">Merck &amp; Co., Inc.</span><br>All rights reserved</p>
<p>usifu-mk4031-pwi-5ml-1408r000</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-21"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 200 mcg Vial Carton</h1>
<p class="First">This carton contains:<br>One <span class="Bold Underline">single-use</span> vial of SYLATRON<br>One <span class="Bold Underline">single-use</span> vial of diluent<br>Two syringes with 1/2-inch 27-gauge needles<br>Two alcohol swabs</p>
<p>NDC 0085-4347-01</p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">SYLATRON</span><span class="Sup">®</span><br> (peginterferon alfa-2b)<br>For Injection</p>
<p>Do not reuse vial<br>Dispense the enclosed<br>Medication Guide to each patient.<br><span class="Bold">Dosage and Administration:</span><br>See package insert. Read accompanying directions.<br>Reconstitute as directed in package insert.</p>
<p><span class="Bold">200 mcg per vial*<br>For Subcutaneous Use<br>Delivers 200 mcg in 0.5 mL.</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 200 mcg Vial Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3874c95c-092e-4cd5-b104-6ed2bc391b0e&amp;name=sylatron-5ml-21.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-22"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 300 mcg Vial Carton</h1>
<p class="First">This carton contains:<br>One <span class="Bold Underline">single-use</span> vial of SYLATRON<br>One <span class="Bold Underline">single-use</span> vial of diluent<br>Two syringes with 1/2-inch 27-gauge needles<br>Two alcohol swabs</p>
<p>NDC 0085-4348-01</p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">SYLATRON</span><span class="Sup">®</span><br> (peginterferon alfa-2b)<br>For Injection</p>
<p>Do not reuse vial<br>Dispense the enclosed<br>Medication Guide to each patient.<br><span class="Bold">Dosage and Administration:</span><br>See package insert. Read accompanying directions.<br>Reconstitute as directed in package insert.</p>
<p><span class="Bold">300 mcg per vial*<br>For Subcutaneous Use<br>Delivers 300 mcg in 0.5 mL.</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 300 mcg Vial Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3874c95c-092e-4cd5-b104-6ed2bc391b0e&amp;name=sylatron-5ml-22.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-23"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 600 mcg Vial Carton</h1>
<p class="First">This carton contains:<br>One <span class="Bold Underline">single-use</span> vial of SYLATRON<br>One <span class="Bold Underline">single-use</span> vial of diluent<br>Two syringes with 1/2-inch 27-gauge needles<br>Two alcohol swabs</p>
<p>NDC 0085-4349-01</p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">SYLATRON</span><span class="Sup">®</span><br> (peginterferon alfa-2b)<br>For Injection</p>
<p>Do not reuse vial<br>Dispense the enclosed<br>Medication Guide to each patient.<br><span class="Bold">Dosage and Administration:</span><br>See package insert. Read accompanying directions.<br>Reconstitute as directed in package insert.</p>
<p><span class="Bold">600 mcg per vial*<br>For Subcutaneous Use<br>Delivers 600 mcg in 0.5 mL.</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 600 mcg Vial Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3874c95c-092e-4cd5-b104-6ed2bc391b0e&amp;name=sylatron-5ml-23.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>SYLATRON 		
					</strong><br><span class="contentTableReg">peginterferon alfa-2b kit</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0085-4347</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0085-4347-01</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Quantity of Parts</td></tr>
<tr>
<th scope="col" width="5" class="formTitle">Part #</th>
<th scope="col" class="formTitle">Package Quantity</th>
<th scope="col" class="formTitle">Total Product Quantity</th>
</tr>
<tr class="formTableRowAlt">
<td width="5" class="formItem"><strong>Part 1</strong></td>
<td class="formItem">1 VIAL </td>
<td class="formItem">0.1 mL</td>
</tr>
<tr class="formTableRow">
<td width="5" class="formItem"><strong>Part 2</strong></td>
<td class="formItem">1 VIAL </td>
<td class="formItem">5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 1 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>SYLATRON  		
					</strong><br><span class="contentTableReg">peginterferon alfa-2b injection, powder, lyophilized, for solution</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">SUBCUTANEOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>peginterferon alfa-2b</strong> (peginterferon alfa-2b) </td>
<td class="formItem">peginterferon alfa-2b</td>
<td class="formItem">40 ug  in 0.1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium phosphate, dibasic anhydrous</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium phosphate, monobasic, dihydrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sucrose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>polysorbate 80</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (White to off-white) </td>
<td class="formLabel">Score</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">0.1 mL in 1 VIAL; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103949</td>
<td class="formItem">03/29/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 2 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>STERILE WATER 		
					</strong><br><span class="contentTableReg">inert injection, solution</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">SUBCUTANEOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">5 mL in 1 VIAL; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103949</td>
<td class="formItem">08/30/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103949</td>
<td class="formItem">08/30/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>SYLATRON 		
					</strong><br><span class="contentTableReg">peginterferon alfa-2b kit</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0085-4348</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0085-4348-01</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Quantity of Parts</td></tr>
<tr>
<th scope="col" width="5" class="formTitle">Part #</th>
<th scope="col" class="formTitle">Package Quantity</th>
<th scope="col" class="formTitle">Total Product Quantity</th>
</tr>
<tr class="formTableRowAlt">
<td width="5" class="formItem"><strong>Part 1</strong></td>
<td class="formItem">1 VIAL </td>
<td class="formItem">0.1 mL</td>
</tr>
<tr class="formTableRow">
<td width="5" class="formItem"><strong>Part 2</strong></td>
<td class="formItem">1 VIAL </td>
<td class="formItem">5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 1 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>SYLATRON  		
					</strong><br><span class="contentTableReg">peginterferon alfa-2b injection, powder, lyophilized, for solution</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">SUBCUTANEOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>peginterferon alfa-2b</strong> (peginterferon alfa-2b) </td>
<td class="formItem">peginterferon alfa-2b</td>
<td class="formItem">60 ug  in 0.1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium phosphate, dibasic anhydrous</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium phosphate, monobasic, dihydrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sucrose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>polysorbate 80</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (White to off-white) </td>
<td class="formLabel">Score</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">0.1 mL in 1 VIAL; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103949</td>
<td class="formItem">03/29/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 2 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>STERILE WATER 		
					</strong><br><span class="contentTableReg">inert injection, solution</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">SUBCUTANEOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">5 mL in 1 VIAL; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103949</td>
<td class="formItem">08/30/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103949</td>
<td class="formItem">03/29/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>SYLATRON 		
					</strong><br><span class="contentTableReg">peginterferon alfa-2b kit</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0085-4349</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0085-4349-01</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Quantity of Parts</td></tr>
<tr>
<th scope="col" width="5" class="formTitle">Part #</th>
<th scope="col" class="formTitle">Package Quantity</th>
<th scope="col" class="formTitle">Total Product Quantity</th>
</tr>
<tr class="formTableRowAlt">
<td width="5" class="formItem"><strong>Part 1</strong></td>
<td class="formItem">1 VIAL </td>
<td class="formItem">0.1 mL</td>
</tr>
<tr class="formTableRow">
<td width="5" class="formItem"><strong>Part 2</strong></td>
<td class="formItem">1 VIAL </td>
<td class="formItem">5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 1 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>SYLATRON  		
					</strong><br><span class="contentTableReg">peginterferon alfa-2b injection, powder, lyophilized, for solution</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">SUBCUTANEOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>peginterferon alfa-2b</strong> (peginterferon alfa-2b) </td>
<td class="formItem">peginterferon alfa-2b</td>
<td class="formItem">120 ug  in 0.1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium phosphate, dibasic anhydrous</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium phosphate, monobasic, dihydrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sucrose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>polysorbate 80</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (White to off-white) </td>
<td class="formLabel">Score</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">0.1 mL in 1 VIAL; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103949</td>
<td class="formItem">03/29/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 2 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>STERILE WATER 		
					</strong><br><span class="contentTableReg">inert injection, solution</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">SUBCUTANEOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">5 mL in 1 VIAL; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103949</td>
<td class="formItem">08/30/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103949</td>
<td class="formItem">03/29/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Merck Sharp &amp; Dohme Corp.
							(001317601)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Schering-Plough (Ireland) Company</td>
<td class="formItem"></td>
<td class="formItem">986118438</td>
<td class="formItem">MANUFACTURE(0085-4347, 0085-4348, 0085-4349), API MANUFACTURE(0085-4347, 0085-4348, 0085-4349)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Merck Sharp &amp; Dohme Corp.</td>
<td class="formItem"></td>
<td class="formItem">101740835</td>
<td class="formItem">LABEL(0085-4347, 0085-4348, 0085-4349), PACK(0085-4347, 0085-4348, 0085-4349)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Baxter Healthcare Corporation</td>
<td class="formItem"></td>
<td class="formItem">001728059</td>
<td class="formItem">MANUFACTURE(0085-4347, 0085-4348, 0085-4349)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 5/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>9728c0aa-f4d7-4f2a-99dd-aed069c0f799</div>
<div>Set id: 3874c95c-092e-4cd5-b104-6ed2bc391b0e</div>
<div>Version: 4</div>
<div>Effective Time: 20150513</div>
</div>
</div> <div class="DistributorName">Merck Sharp &amp; Dohme Corp.</div></p>
</body></html>
